A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

Since Henry Bence Jones first discovered a urine protein marker for multiple myeloma in 1846, the field of cancer biomarkers has grown exponentially. Over the past two centuries, scientists have ...

Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...

Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...